Clinical data
| Fig. no. . | Diagnosis . | No. . | Sex F/M . | Age (y) mean (range) . | Tumor stage* (no. of cases) . | Anti-AChR antibody titer (nmol/L)† mean (range) . | Treatment‡ (no. of cases) . | Thymoma subgroups . | |||
|---|---|---|---|---|---|---|---|---|---|---|---|
| CT MG+ . | MXT MG+ . | CT MG− . | MXT MG− . | ||||||||
| 1 | Tm | 15 | 9/6 | 55.1 (33-75) | II (12); III (1); IVa (2) | 60.2 (3-342) | None | 8 | 1 | 4 | 2 |
| TFH | 11 | 10/1 | 25.9 (13-36) | — | 24.7 (0.5-87) | None | — | — | — | — | |
| 2 | Tm | 15 | 9/6 | 55.1 (33-75) | II (12); III (1); IVa (2) | 60.2 (3-342) | None | 8 | 1 | 4 | 2 |
| TFH | 7 | 7/0 | 27.2 (13-36) | — | 33.0 (1-87) | None | — | — | — | — | |
| 3A | resT | 9 | 7/2 | 52.4 (33-79) | I (2); II (6); IVa (1) | 25.7 (10-70) | Steroids (2) | 8 | 1 | — | — |
| Tm | 19 | 14/5 | 54.1 (33-79) | I (2); II (13); III (2); IVa (2) | 30.6 (3-71) | Steroids (1) | 10 | 3 | 3 | 3 | |
| TFH | 11 | 10/1 | 25.9 (13-36) | — | 24.7 (0.5-87) | None | — | — | — | — | |
| 3B | Tm | 9 | 6/3 | 57.8 (36-79) | II (7); III (1); IVa (1) | 34.3 (17-67) | Steroids (1) | 2 | 1 | 3 | 3 |
| TFH | 7 | 7/0 | 27.2 (13-36) | — | 33.0 (1-87) | None | — | — | — | — | |
| 4A | Tm | 12 | 7/5 | 54.2 (33-75) | II (10); IVa (2) | 64.6 (2-342) | None | 7 | 1 | 1 | 3 |
| TFH | 3 | 3/0 | 21.7 (13-32) | — | 26.0 (12-44) | None | — | — | — | — | |
| 4B | Tm | 10 | 6/4 | 53.2 (33-75) | II (9); IVa (1) | 72.2 (3-342) | None | 5 | 1 | 1 | 3 |
| 5 | AChR | 20 | 13/7 | 53.6 (29-75) | I (2); II (15); III (2); IVa (1) | 20.8 (3-70) | Steroids (2) | 16 | 4 | — | — |
| NF-M | 16 | 12/4 | 52.3 (29-68) | I (1); II (12); III (2); IVa (1) | 19.0 (3-65) | Steroids (2) | 14 | 2 | — | — | |
| TT | 14 | 10/4 | 57.6 (33-75) | I (2); II (9); III (3) | 18.2 (3-62) | Steroids (2) | 10 | 4 | — | — | |
| Med | 6 | 3/3 | 67.8 (60-74) | I (2); II (4) | ND MG+ (3 cases) | Steroids (3) | — | — | — | — | |
| Fig. no. . | Diagnosis . | No. . | Sex F/M . | Age (y) mean (range) . | Tumor stage* (no. of cases) . | Anti-AChR antibody titer (nmol/L)† mean (range) . | Treatment‡ (no. of cases) . | Thymoma subgroups . | |||
|---|---|---|---|---|---|---|---|---|---|---|---|
| CT MG+ . | MXT MG+ . | CT MG− . | MXT MG− . | ||||||||
| 1 | Tm | 15 | 9/6 | 55.1 (33-75) | II (12); III (1); IVa (2) | 60.2 (3-342) | None | 8 | 1 | 4 | 2 |
| TFH | 11 | 10/1 | 25.9 (13-36) | — | 24.7 (0.5-87) | None | — | — | — | — | |
| 2 | Tm | 15 | 9/6 | 55.1 (33-75) | II (12); III (1); IVa (2) | 60.2 (3-342) | None | 8 | 1 | 4 | 2 |
| TFH | 7 | 7/0 | 27.2 (13-36) | — | 33.0 (1-87) | None | — | — | — | — | |
| 3A | resT | 9 | 7/2 | 52.4 (33-79) | I (2); II (6); IVa (1) | 25.7 (10-70) | Steroids (2) | 8 | 1 | — | — |
| Tm | 19 | 14/5 | 54.1 (33-79) | I (2); II (13); III (2); IVa (2) | 30.6 (3-71) | Steroids (1) | 10 | 3 | 3 | 3 | |
| TFH | 11 | 10/1 | 25.9 (13-36) | — | 24.7 (0.5-87) | None | — | — | — | — | |
| 3B | Tm | 9 | 6/3 | 57.8 (36-79) | II (7); III (1); IVa (1) | 34.3 (17-67) | Steroids (1) | 2 | 1 | 3 | 3 |
| TFH | 7 | 7/0 | 27.2 (13-36) | — | 33.0 (1-87) | None | — | — | — | — | |
| 4A | Tm | 12 | 7/5 | 54.2 (33-75) | II (10); IVa (2) | 64.6 (2-342) | None | 7 | 1 | 1 | 3 |
| TFH | 3 | 3/0 | 21.7 (13-32) | — | 26.0 (12-44) | None | — | — | — | — | |
| 4B | Tm | 10 | 6/4 | 53.2 (33-75) | II (9); IVa (1) | 72.2 (3-342) | None | 5 | 1 | 1 | 3 |
| 5 | AChR | 20 | 13/7 | 53.6 (29-75) | I (2); II (15); III (2); IVa (1) | 20.8 (3-70) | Steroids (2) | 16 | 4 | — | — |
| NF-M | 16 | 12/4 | 52.3 (29-68) | I (1); II (12); III (2); IVa (1) | 19.0 (3-65) | Steroids (2) | 14 | 2 | — | — | |
| TT | 14 | 10/4 | 57.6 (33-75) | I (2); II (9); III (3) | 18.2 (3-62) | Steroids (2) | 10 | 4 | — | — | |
| Med | 6 | 3/3 | 67.8 (60-74) | I (2); II (4) | ND MG+ (3 cases) | Steroids (3) | — | — | — | — | |
According to Masaoka and colleagues.37
Refers to titers of myasthenic thymoma patients (all nonmyasthenic patients have titers < 0.5 nmol/L).
Immunosuppressive treatment.
AChR indicates acetylcholine receptor; CT, cortical thymoma; MG, myasthenia gravis; Med, medullary thymoma; MXT, mixed thymoma; ND, not determined; NF-M, midsize neurofilament; resT, residual thymus; TFH, thymic follicular hyperplasia; Tm, thymoma.
Overlap among patients analyzed by FACS and proliferation assay: PBL from 4 of 9 myasthenic thymoma patients, thymocytes from 10 of 13 myasthenic thymoma patients, and PBL from 6 healthy controls were analyzed by FACS and standard T-cell proliferation assays.